Maravai LifeSciences Holdings, Inc. cash flow to debt ratio of -161.81% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Maravai LifeSciences Holdings, Inc.'s free cash flow has decreased 218.67% from $-22.19M last year to $-70.72M, signaling decreasing performance

Maravai LifeSciences Holdings, Inc.'s debt to equity ratio is 0.86, which means that the company's assets are unhealthy financed, signaling financial risk.

Maravai LifeSciences Holdings, Inc.'s debt has decreased relative to shareholder equity from 1.16 last year to 0.86 today, signaling strengthened financials

Maravai LifeSciences Holdings, Inc. has a net cash position, so leverage is healthy.

Maravai LifeSciences Holdings, Inc.'s interest coverage ratio of 4.01 indicates that earnings with good margin can cover interest payments on company debt

Maravai LifeSciences Holdings, Inc.'s profit margin has increased (-33.67%) in the last year from -55.89% to -37.07%, signaling increasing performance

Maravai LifeSciences Holdings, Inc.'s short-term assets of $296.25M exceed its short-term liabilities of $44.92M

Maravai LifeSciences Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Maravai LifeSciences Holdings, Inc.'s return on equity of -35.42%, is lower than 15.00%, indicating bad performance

Maravai LifeSciences Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Maravai LifeSciences Holdings, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Maravai LifeSciences Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Maravai LifeSciences Holdings, Inc. has negative free cash flow, indicating cash burn

Maravai LifeSciences Holdings, Inc.'s yearly earnings has increased -9.72% since last year from $-144.85M to $-130.77M, signaling increasing performance

Maravai LifeSciences Holdings, Inc.'s yearly revenue has decreased 28.34% since last year from $259.19M to $185.74M, signaling decreasing performance

ROIC 16.91% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Maravai LifeSciences Holdings, Inc.'s 3-year revenue CAGR of -40.53% is negative, indicating declining revenue over the past 3 years

Maravai LifeSciences Holdings, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Maravai LifeSciences Holdings, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Maravai LifeSciences Holdings, Inc. has insufficient data to evaluate this check.

Maravai LifeSciences Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Maravai LifeSciences Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Maravai LifeSciences Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Maravai LifeSciences Holdings, Inc. has insufficient data to evaluate this check.

Maravai LifeSciences Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Maravai LifeSciences Holdings, Inc. has a price-to-book ratio of 2.53x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Maravai LifeSciences Holdings, Inc. has a price-to-sales ratio of 4.30x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue